AGC Biologics is to produce clinical drugs for antibody-based therapies at its Seattle manufacturing site. Credit: unpict/Shutterstock.com. AGC Biologics has entered an agreement with Asahi
CRESEMBA is intended for the treatment of invasive aspergillosis or invasive mucormycosis. Credit: Prostock studio/Shutterstock.com. The US Food and Drug Administration (FDA) has accepted Astellas
City of Hope’s Saul Priceman is conducting research on CAR T cell therapy. Credit: City of Hope/ PRNewswire. Researchers at City of Hope, one of
Glecirasib is intended for the treatment of pancreatic cancer patients with the KRAS G12C mutation. Credit: Nemes Laszlo/Shutterstock.com. Jacobio Pharma has received breakthrough therapy designation
GA Depot is intended for the treatment of relapsing forms of multiple sclerosis. Credit: Zerbor/Shutterstock.com. The US Food and Drug Administration (FDA) has accepted for
IZERVAY is an avacincaptad pegol intravitreal solution. Credit: Astellas Pharma Inc/ PRNewswire. IVERIC bio, an Astellas company, has received clearance from the US Food and
Hu14.18 is in development for the treatment of newly diagnosed high-risk neuroblastoma. Credit: Kateryna Kon/Shutterstock.com. Renaissance Pharma has signed an agreement to in-license St Jude
Zolbetuximab is intended for treating patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma. Credit: meeboonstudio/Shutterstock.com. The Center for Drug Evaluation (CDE) of the China National
LIVMARLI has been now authorised in Canada to treat cholestatic pruritus in patients with Alagille syndrome. Credit: Shidlovski /Shutterstock.com. Mirum Pharmaceuticals has received approval from
The medicine may slow down breathing rate, cause allergic reactions and constipation. Credit: BlurryMe/Shutterstock.com. The UK Medicines and Healthcare Products Regulatory Agency (MHRA) is consulting